GlaxoSmithKline Pharmaceuticals Ltd. reported a consolidated net profit of ₹237.18 crore for the quarter ending June 30, 2026. This figure represents a 15.7% increase over the same period last year. Revenue from operations reached ₹938.44 crore for the quarter.
Strong performance in the general medicines and vaccine segments supported the positive results. The company re-appointed Bhushan Akshikar as Managing Director for an additional two-year term to ensure leadership stability.
Future growth plans center on new product launches, including the multiple myeloma drug Blenrep. The company also expects the Arexvy RSV vaccine to contribute to long-term expansion.